Bioequivalence CROs

Dhaka-based CRO providing clinical trial management and bioequivalence studies for Bangladesh's pharmaceutical industry, one of the largest generic drug markets in South Asia.

Ho Chi Minh City-based Vietnamese CRO providing Phase II-IV clinical trial management, BA/BE studies, and regulatory consulting for pharmaceutical companies entering the Vietnamese market.

Celerion's clinical pharmacology facility in Lincoln, Nebraska, providing early-phase clinical trials, BA/BE studies, and cardiac safety testing with a 200+ bed Phase I unit.

Santiago-based Phase I clinical pharmacology unit providing first-in-human, BA/BE, and pharmacokinetic studies for Latin American and international sponsors under ICH-GCP standards.

Adelaide-based Australian Phase I clinical pharmacology unit within the Royal Adelaide Hospital, conducting first-in-human, BA/BE, and cardiac safety studies with a 48-bed facility.

Jakarta-based Indonesian CRO and bioanalytical laboratory providing BA/BE studies, clinical trials, and analytical services for pharmaceutical companies seeking Indonesian regulatory approval.

Welsh-based early-phase CRO providing Phase I clinical pharmacology, FTIH studies, and paediatric clinical trials with a 72-bed residential unit and dedicated bioanalytical laboratory.

Indian bioanalytical and clinical research laboratory providing BA/BE studies, pharmacokinetic analysis, and analytical method development for generic and innovative drug programs.

Amman-based Jordanian CRO and pharmaceutical company providing bioequivalence studies, BA/BE clinical trials, and contract analytical services for MENA pharmaceutical markets.

Ahmedabad-based CRO with a 350-bed Phase I clinical pharmacology unit, specializing in early-phase clinical trials, BA/BE studies, and bioanalytical services for global pharma clients.